Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breakpoints for Predicting <i>Pseudomonas aeruginosa</i> Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips

1 Sept 2005

Abstract excerpt

Inhaled administration of tobramycin assures high concentrations in cystic fibrotic lungs, improving the therapeutic ratio over that of parenteral tobramycin levels, particularly against Pseudomonas aeruginosa. Conventional Clinical and Laboratory Standards Institute (CLSI; formerly National Committee for Clinical Laboratory Standards) breakpoints only consider parenteral levels and do not take into account these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial biofilms and quorum sensing
Share to Cystic Fibrosis Research Advances
Share to Inhalation and Respiratory Drug Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16145095
DOI: 10.1128/jcm.43.9.4480-4485.2005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breakpoints for Predicting <i>Pseudomonas aeruginosa</i> Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest StripsPMID 16145095Read ↗

Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.Semantic proximity Read ↗

Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.Semantic proximity Read ↗

Establishing MIC breakpoints and the interpretation of <i>in vitro</i> susceptibility testsSemantic proximity Read ↗

Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint indexSemantic proximity Read ↗

Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa.Semantic proximity Read ↗

Is a New Standard Needed for Diffusion Methods for In Vitro Susceptibility Testing of Fosfomycin against Pseudomonas aeruginosa?Semantic proximity Read ↗

Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion.Semantic proximity Read ↗

Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophiliaSemantic proximity Read ↗

Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment.Semantic proximity Read ↗

Aminoglycoside‐Resistance Mechanisms for Cystic FibrosisPseudomonas aeruginosaIsolates Are Unchanged by Long‐Term, Intermittent, Inhaled Tobramycin TreatmentSemantic proximity Read ↗

Pulmonary deposition of inhaled tobramycin prior to and after respiratory therapy and use of inhaled albuterol in cystic fibrosis patients colonized with Pseudomonas aeruginosa.Semantic proximity Read ↗

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.